Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
What's azacitidine's effect on gvhd associated dna?How do clinical trials prove polivy's effectiveness?How does lipitor compare to crestor in long term heart disease risk reduction?Lipitor dosage for athletic performance?Does timing affect lipitor's effectiveness?
See the DrugPatentWatch profile for ibrance
What is Ibrance for cancer treatment? Ibrance, also known as palbociclib, is a kinase inhibitor medication used in combination with other cancer treatments to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative (HER2-negative) advanced or metastatic breast cancer in postmenopausal women. [1] According to a study published by Pfizer, the manufacturer of Ibrance, the medication works by blocking the activity of a protein called cyclin-dependent kinase 4 and 6 (CDK4/6), which is involved in the growth and spread of cancer cells. Comparison with other breast cancer treatments Ibrance is often used in combination with hormone therapies, such as tamoxifen or letrozole, to treat breast cancer. While Ibrance has shown promise in improving progression-free survival in patients with advanced breast cancer, its long-term effects and interactions with other medications are still being studied. Side effects and patient concerns The most common side effects of Ibrance include fatigue, nausea, diarrhea, anemia, and infections. Patients should discuss the potential risks and benefits of Ibrance with their healthcare provider to determine if it is the right treatment option for them. Patent expiration and exclusivity As of DrugPatentWatch.com , Ibrance's patent expired in 2025, which may allow other manufacturers to produce similar medications. However, the availability of biosimilars or generic versions of Ibrance is subject to change and may be influenced by various regulatory and market factors. [2] According to the FDA, Ibrance's approval was based on a clinical study that demonstrated its safety and efficacy in treating patients with advanced breast cancer. However, as with any medication, patients should be cautious and closely monitor their condition when using Ibrance. References [1] Pfizer. (2022). Ibrance (palbociclib) Prescribing Information. [2] U.S. Food and Drug Administration. (2015). FDA Approval Letter for Ibrance (palbociclib). Note: The answer is based on publicly available information and may not reflect the most up-to-date or comprehensive insights on the topic.
Other Questions About Ibrance :